MIDOSTAURIN
Approved in September 2017 for formulary use for the treatment of acute myeloid leukemia (AML). All other indications require patients to use their own supply. Pharmacy has 24 hours to procure the medication once ordered for AML indication.
Approved in September 2017 for formulary use for the treatment of acute myeloid leukemia (AML). All other indications require patients to use their own supply. Pharmacy has 24 hours to procure the medication once ordered for AML indication.